Video

Dr. Demetri on the Evolving Field of Sarcoma

George D. Demetri, MD, senior vice president for Experimental Therapeutics at the Dana-Farber Cancer Institute, professor of Medicine at Harvard Medical School, and co-director of the Ludwig Center at Harvard, discusses the evolving and advancing field of sarcoma.

George D. Demetri, MD, senior vice president for Experimental Therapeutics at the Dana-Farber Cancer Institute, professor of Medicine at Harvard Medical School, and co-director of the Ludwig Center at Harvard, discusses the evolving and advancing field of sarcoma.

Providing patients with more precise sarcoma diagnoses helps better drive treatment decisions and appropriately matches patients with clinical trials. This mindset has translated into other tumor types, as well, Demetri explains.

Additionally, targeted therapies such as TREK-1 inhibitors are showing promise as a potential treatment for patients with sarcoma. Findings from clinical trials examining immunotherapeutic agents in this patient population are likely to be presented at the 2016 ASCO Annual Meeting, he adds.

Sarcoma is also leading the way in the epigenetic space; for example, subtypes including malignant rhabdoid tumors, synovial sarcomas, and epithelioid sarcomas could be treated with H2 inhibitors. Additionally, the breakthrough therapy designation of the affinity enhanced T-cell therapy is “the tip of the iceberg,” in this realm of research, Demetri says.

Related Videos
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Coral Olazagasti, MD
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Tycel Phillips, MD
Giuseppe Curigliano, MD, PhD
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Andrew Davis, MD
Noa Biran, MD